In recognition of Harrison's work, 36,598,968 options (2% of issued capital) have been offered to align her long term incentive with that of shareholders.
In other moves, Dr James Williams who is a co-founder of the company and current executive chairman, will transition to non-executive chairman.
Dr Williams commented:
"In the time since her appointment, Kathy has clearly demonstrated her commitment as Dimerix’s CEO and ability in the role.
"The Dimerix board is fully committed to supporting Kathy as she leads and implements the company’s commercialisation strategy for DMX-200."
Kathy Harrison discusses outcome of DMX-200 trial
Importance of Phase 2a results
The importance of Dimerix's Phase 2a results is that the trial meets the primary safety endpoint and demonstrates encouraging efficacy in a clinically meaningful number of patients.
- 25% of patients achieved a greater than 50% reduction in proteinuria, beyond that achieved with the highest dosage of current standard of care therapy; and
- 45% of patients granted ability to continue ongoing treatment under Special Access Scheme upon recommendation of their advising physician, confirming confidence in the treatment.
The clinically meaningful reductions in proteinuria are highly encouraging and support the rationale behind the program.
Given this is a “hard to treat” patient group, Dimerix now have a very strong indication that the treatment is having a significant impact in slowing the progression of Chronic Kidney Disease.